These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 38832950)
1. Prevalence, incidence and treatment patterns of prurigo nodularis in England: a retrospective database analysis. Bahloul D; Hudson R; Balogh O; Mathias E; Heywood B; Hubbuck E; Diribe O; McDonald R; Bewley A Br J Dermatol; 2024 Sep; 191(4):548-555. PubMed ID: 38832950 [TBL] [Abstract][Full Text] [Related]
2. Estimating the healthcare burden of Prurigo Nodularis in England: a CPRD database study. Bahloul D; Hudson R; Balogh O; Mathias E; Heywood B; Hubbuck E; Tavi J; Diribe O; McDonald R; Wiggins S; Bewley AP J Dermatolog Treat; 2024 Dec; 35(1):2367615. PubMed ID: 38945539 [No Abstract] [Full Text] [Related]
3. Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years. Yokozeki H; Murota H; Matsumura T; Komazaki H; Br J Dermatol; 2024 Jul; 191(2):200-208. PubMed ID: 38629497 [TBL] [Abstract][Full Text] [Related]
4. Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need. Pereira MP; Basta S; Moore J; Ständer S J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2224-2229. PubMed ID: 29869425 [TBL] [Abstract][Full Text] [Related]
5. Epidemiology of prurigo nodularis in England: a retrospective database analysis. Morgan CL; Thomas M; Ständer S; Jabbar-Lopez ZK; Piketty C; Gabriel S; Currie CJ; Puelles J Br J Dermatol; 2022 Aug; 187(2):188-195. PubMed ID: 35083742 [TBL] [Abstract][Full Text] [Related]
6. Prurigo nodularis: new insights into pathogenesis and novel therapeutics. Liao V; Cornman HL; Ma E; Kwatra SG Br J Dermatol; 2024 May; 190(6):798-810. PubMed ID: 38345154 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. Sofen H; Bissonnette R; Yosipovitch G; Silverberg JI; Tyring S; Loo WJ; Zook M; Lee M; Zou L; Jiang GL; Paolini JF EClinicalMedicine; 2023 Mar; 57():101826. PubMed ID: 36816342 [TBL] [Abstract][Full Text] [Related]
8. Increased cardiovascular risks and mortality in prurigo nodularis: a global cohort study. Olbrich H; Kridin K; Hernández G; Zirpel H; Sadik CD; Terheyden P; Thaçi D; Ludwig RJ; Boch K EBioMedicine; 2024 May; 103():105123. PubMed ID: 38631094 [TBL] [Abstract][Full Text] [Related]
9. Prevalence of Prurigo Nodularis in Poland. Ryczek A; Reich A Acta Derm Venereol; 2020 May; 100(10):adv00155. PubMed ID: 32421199 [TBL] [Abstract][Full Text] [Related]
10. Disease burden and treatment satisfaction in patients with prurigo nodularis in Japan. Murota H; Arima K; Yoshida T; Fujita H J Dermatol; 2024 Feb; 51(2):223-233. PubMed ID: 38066728 [TBL] [Abstract][Full Text] [Related]
11. Comorbidities, healthcare resource utilization & treatment pattern among patients with prurigo nodularis, compared to a benchmark in Germany: A real-world evidence claims data study. Ständer S; Ketz M; Akumo D; Kossack N; Pignot M; Chavda R; Gabriel S J Eur Acad Dermatol Venereol; 2024 May; 38(5):883-894. PubMed ID: 38078642 [TBL] [Abstract][Full Text] [Related]
12. The effectiveness and safety of dupilumab in the management of refractory prurigo nodularis in 45 Chinese patients: A real-life observational study. Fang HY; Lian CH J Dermatol; 2023 Aug; 50(8):1084-1087. PubMed ID: 37088954 [TBL] [Abstract][Full Text] [Related]
13. Clinical Characteristics and Treatment Outcomes of Prurigo Nodularis: A Retrospective Study. Taghaddos D; Savinova I; Abu-Hilal M J Cutan Med Surg; 2024; 28(2):141-145. PubMed ID: 38281092 [TBL] [Abstract][Full Text] [Related]
14. Ethnic differences and comorbidities of 909 prurigo nodularis patients. Boozalis E; Tang O; Patel S; Semenov YR; Pereira MP; Stander S; Kang S; Kwatra SG J Am Acad Dermatol; 2018 Oct; 79(4):714-719.e3. PubMed ID: 29733939 [TBL] [Abstract][Full Text] [Related]
15. Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis. Williams KA; Roh YS; Brown I; Sutaria N; Bakhshi P; Choi J; Gabriel S; Chavda R; Kwatra SG Expert Rev Clin Pharmacol; 2021 Jan; 14(1):67-77. PubMed ID: 33191806 [No Abstract] [Full Text] [Related]
16. Validation of a scoring algorithm for the clinician-reported outcome tool 'prurigo activity and severity (PAS)' based on clinical studies of dupilumab in adults with prurigo Nodularis. Zeidler C; Stander S; Rhoten S; Wratten S; Zhang D; Msihid J; Brookes E; Thomas R; Bahloul D J Eur Acad Dermatol Venereol; 2024 Oct; 38(10):1954-1964. PubMed ID: 38563058 [TBL] [Abstract][Full Text] [Related]
17. The Sleep Disturbance Numerical Rating Scale: Content Validity, Psychometric Validation, and Meaningful Within-Patient Change in Prurigo Nodularis. Ständer S; Fofana F; Dias-Barbosa C; Rodriguez D; Budhiarso I; Jabbar-Lopez ZK; Piketty C; Vernon M; Puelles J Dermatol Ther (Heidelb); 2023 Jul; 13(7):1587-1602. PubMed ID: 37329468 [TBL] [Abstract][Full Text] [Related]
18. Epidemiology, Comorbidities, and Prescription Patterns of Korean Prurigo Nodularis Patients: A Multi-Institution Study. Woo YR; Wang S; Sohn KA; Kim HS J Clin Med; 2021 Dec; 11(1):. PubMed ID: 35011837 [TBL] [Abstract][Full Text] [Related]
19. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response. Husein-ElAhmed H; Steinhoff M J Dermatolog Treat; 2022 May; 33(3):1547-1553. PubMed ID: 33200955 [TBL] [Abstract][Full Text] [Related]
20. Prurigo nodularis: retrospective study of 13 cases managed with methotrexate. Spring P; Gschwind I; Gilliet M Clin Exp Dermatol; 2014 Jun; 39(4):468-73. PubMed ID: 24825138 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]